Comparative safety of high-dose versus standard-dose influenza vaccination in patients with end-stage renal disease.

CONCLUSIONS: The risks of serious adverse events were low and similar between treatment groups; however, HDV recipients had increased risks of several milder adverse events compared with SDV recipients, consistent with clinical trial findings in the general population of older adults. These results add important information to inform the risk-benefit tradeoff of the use of HDV versus SDV in patients with ESRD.
PMID: 32565346 [PubMed - as supplied by publisher]

Source: Vaccine - June 17, 2020 Category: Allergy & Immunology Authors: Layton JB, McGrath LJ, Sahrmann JM, Ma Y, Dharnidharka VR, O'Neil C, Weber DJ, Butler AM Tags: Vaccine Source Type: research